Substantial data from clinical trials and epidemiological studies show promising results for use of statins in many cancers, including mammary carcinoma. Breast tumor primarily metastasizes to bone to form osteolytic lesions, causing severe pain and pathological fracture. Here, we report that simvastatin acts as an inhibitor of osteolysis in a mouse model of breast cancer skeletal metastasis of human mammary cancer cell MDA-MB-231, which expresses the mutant p53R280K. Simvastatin and lovastatin attenuated migration and invasion of MDA-MB-231 and BT-20 breast tumor cells in culture. Acquisition of phenotype to express the cancer stem cell marker, CD44, leads to invasive potential of the tumor cells. Interestingly, statins significantly decreased the expression of CD44 protein via a transcriptional mechanism. shRNA-mediated down-regulation of CD44 markedly reduced the migration and invasion of breast cancer cells in culture. We identified that in the MDA-MB-231 cells, simvastatin elevated the levels of mutated p53R280K, which was remarkably active as a transcription factor. shRNAderived inhibition of mutant p53R280K augmented the expression of CD44, leading to increased migration and invasion. Finally, we demonstrate an inverse correlation between expression of p53 and CD44 in the tumors of mice that received simvastatin. Our results reveal a unique function of statins, which foster enhanced expression of mutant p53R280K to prevent breast cancer cell metastasis to bone.Statins are potent inhibitors of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the mevalonate pathway for the biosynthesis of cholesterol (1). These compounds have been used for decades as safe and effective drugs in the control of hypercholesterolemia. The mevalonate pathway also produces a number of important end products, which include isoprenoid precursors, ubiquinone, dolichol, and isopentenyladenine (2). Statins also show anti-carcinogenic effects in rodent models of lung, prostate, melanoma, colon, glioma, and mammary tumorigenesis, and beneficial effects of statins have been seen in different cancers, including breast cancer (2, 3). For example, a significant 20% reduction in overall cancer risk was observed in patients with statin use (4). A recent study conducted in women who used statins showed significantly reduced risk of breast cancer as compared with nonusers (5). Moreover, an independent study of women who used statins for more than 4 years reported a significantly lower risk of breast cancer in this group (6).Several distinct mechanisms have been proposed whereby statins block tumor cell proliferation and induce apoptosis. For example, inhibition of geranylgeranyl pyrophosphate and farnesyl pyrophosphate production by statins prevents the post-translational modification of Rho and Ras GTPases necessary for their membrane localization (2). Rho proteins regulate the proliferative and invasive potential of various tumor cells, including breast cancer cells (2). Thus, suppression of geranylge...